بایگانی برچسب برای: Pulmonary

Pulmonary.Vasculature.Redox.Signaling.in.Health.and.Disease.[taliem.ir]

Pulmonary Vasculature Redox Signaling in Health and Disease

Pulmonary arterial hypertension (PAH) is a progressive disease of the lung vasculature, which is characterized by sustained pulmonary arterial pressure, resulting in increased pulmonary vascular resistance, with eventual right heart failure . Vascular remodeling caused by the medial hyperplasia of pulmonary artery (PA) smooth muscle cells is a hallmark feature of PAH , which causes occlusion of the vessels . In most forms of PAH, muscularization of small distal PA occurs , and is further characterized by excessive vascular cell proliferation, inward remodeling, rarefaction, and a loss of compliance of the pulmonary blood vessels . Increased resistance to blood flow and more rigid blood vessels (loss of vascular compliance) leads to failure of the right ventricle and eventual death. PAH is more frequent in women than men, and left untreated has a survival time of 5–7 years post diagnosis . From a therapeutic standpoint, there are a number of vasodilator drugs that are indicated for the treatment of PAH, but none of the current therapeutics offers long-term success for survival due to limited effectiveness and unwanted side effects , and more importantly, do not address the underlying causes of the disease.
Pulmonary.Hypertension.and.Interstitial.Lung.[taliem.ir]

Pulmonary Hypertension and Interstitial Lung Disease

Interstitial lung diseases (ILD) is a heterogeneous group of over 200 different diseases of unknown and known cause with common functional characteristics (restrictive physiology and impaired gas exchange) and a common fnal pathway, eventually leading to irreversible fbrosis . In this chapter, the radiographic imaging of the more common conditions of ILD is reviewed, and in particular, Idiopathic Interstitial Pneumonias (IIP), in relation to the presence of pulmonary hypertension, is discussed. A special emphasis is placed on the role of high-resolution computed tomography (HRCT) fndings in association with Pulmonary Hypertension (PH) . In 2002, the ATS/ERS multidisciplinary panel proposed a classifcation of IIP that comprises clinical– pathological entities such as Idiopathic Pulmonary Fibrosis. (IPF), Nonspecifc Interstitial Pneumonia (NSIP), Respiratory Bronchiolitisassociated Interstitial Lung Disease (RB-ILD), Cryptogenic Organizing Pneumonia (COP), Acute Interstitial Pneumonia (AIP), Desquamative Interstitial Pneumonia .(DIP), and lymphoid interstitial pneumonia (LIP) IPF is the most common subset IIP occurring most frequently in patients older than 50 years of age, limited to the lower lungs, and associated with a histological pattern termed usual interstitial pneumonia (UIP). Symptoms include dry cough, progressive dyspnea, and fnger clubbing that usually precede presentation by 6 months [10–18]. Physiological examination shows crackles over the lower lungs specifc for IPF with a high level of accuracy near 100%. In our opinion, only two approaches would allow an earlier diagnosis of IPF: (a) assessment of Velcro crackles by lung auscultation and (b) screening using HRCT.
Diagnosis.and.Treatment.of.Pulmonary.Hypertension.[taliem.ir]

Diagnosis and Treatment of Pulmonary Hypertension

The clinical classifcation of pulmonary hypertension is intended to categorize in fve groups of multiple clinical conditions according to similar clinical presentation, pathological fndings, hemodynamic characteristics, and treatment strategy, as follows: (1) pulmonary arterial hypertension (PAH), (2) pulmonary hypertension due to left heart disease, (3) pulmonary hypertension due to lung diseases and/or hypoxia, (4) chronic thromboembolic pulmonary hypertension (CTEPH) and other pulmonary artery obstructions, and (5) pulmonary hypertension with unclear and/or multifactorial mechanisms.
Clinical Management of[taliem.ir]

Clinical Management of Pulmonary Disorders and Diseases

Non-small cell lung cancer (NSCLC) is a serious health problem. Identifying factors affecting quality of life (QoL) may help modify risk factors and improve survival. The study included 180 patients treated for NSCLC in the Lower Silesian Center of Lung Diseases between January and December 2015. QoL was assessed with QLQ-C30 and QLQ-LC13 scales. General physical functioning was measured with the ECOG Performance Status scale. The clinical and sociodemographic data were retrieved from medical records. The influence of clinical and sociodemographic factors on QoL was examined. NSCLC reduced the global QoL (47.1  23.4) and emotional functioning (57.8  28.8); cognitive functioning was affected in least (76.0  21.0). The patients reported fatigue (42.2  26.2), sleep problems (42.0  30.8), cough (49.8  24.0), and taking analgesics (50.3  37.1) as the most limiting factors. The worsening of a health condition expressed by the length of malignant disease; the presence of comorbidities, metastases, the cluster of symptoms, worse spirometric indices, and living alone had a negative influence on QoL. In conclusion, patients with NSCLC experience reduced QoL and emotional functioning. Proper treatment of comorbidities and symptom management may improve QoL in these patients.